



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

FILE COPY

September 05, 2002

Nicholas Tantillo
Barr Laboratories
2 Quaker Road
P.O. Box 2900
Pomona, NY 10970-0519

Dear Mr. Tantillo:

Your petition requesting the Food and Drug Administration to determine whether Niaspan Tablets, NDA 020381, have been voluntarily discontinued from marketing for reasons of safety or effectiveness, was received by this office on 09/05/02. It was assigned docket number 02P-0400/CP 1 and it was filed on 09/05/02. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

A handwritten signature in cursive script, reading "Gloria Ortega", is written over the typed name.

Gloria Ortega
Dockets Management Branch

02P-0400

ACK 1